IRADIMED CORPORATION

What they do

IRADIMED develops and markets non-magnetic medical devices for use during MRI procedures, primarily the patented MRidium IV infusion pump systems and the 3880 patient vital signs monitoring system. The company generates revenue from device sales, proprietary disposable tubing sets, extended maintenance agreements, and services. It sells directly in the U.S. through a field sales force and internationally through independent distributors.

Revenue drivers

• MRI Compatible IV Infusion Pump Systems — Includes the new MRidium 3870 (introduced in 2025) and the legacy 3860+, which is being discontinued in 2026. Revenue for Q1 2026 was $7.7 million, up from $6.0 million in Q1 2025.
• MRI Compatible Patient Vital Signs Monitoring Systems — The 3880 system monitors vital signs in the MRI environment. Q1 2026 revenue was $7.1 million, up from $6.5 million in Q1 2025.
• Disposables and Services — Recurring revenue from proprietary disposable IV tubing sets, services, and amortization of extended maintenance agreements. Q1 2026 disposables were $4.9 million, services and other $1.0 million, and extended maintenance amortization $0.7 million.

Recent performance

For Q1 2026 (three months ended March 31, 2026), total revenue was $22.0 million, up 13% year-over-year from $19.5 million. Net income rose 24% to $5.8 million, and diluted EPS grew 22% to $0.45. Non-GAAP diluted EPS was $0.49, up 17%. Operating income increased 33% to $7.2 million. The most recent quarter reported (Q2 2026) showed revenue of $20.5 million, down from $22.0 million in Q1, with net income of $5.2 million and diluted EPS of $0.41.

Strategy

Management has launched the next-generation 3870 IV infusion pump system and is transitioning customers from the older 3860+ platform, which will be discontinued during 2026. They expect significant 3870 shipments to begin in Q2 2026, with revenue growth accelerating in the back half of the year. The company continues to invest in sales and marketing, regulatory, and general and administrative expenses. It maintains a strong balance sheet with $59.1 million in cash and equivalents and no significant liabilities.

Risks

• Product concentration — The company relies on a limited number of products—primarily the MRidium IV infusion pump and the 3880 monitoring system—so any disruption in sales or acceptance could materially hurt results.
• Supply chain dependence — The company depends on third-party suppliers for certain raw materials and components; any supply chain disruption could affect manufacturing and revenue.
• Regulatory compliance — As a medical device manufacturer, the company and its suppliers are subject to strict regulatory requirements; any failure to maintain compliance could impact operations.
• Transition to 3870 platform — The discontinuation of the 3860+ line and the shift to the 3870 could result in temporary sales disruption or slower-than-expected customer adoption, as seen in the sequential decline in Q2 2026 revenue.

Outlook

For fiscal 2026, management expects revenue of $91.0 million to $96.0 million, GAAP diluted EPS of $1.90 to $2.05, and non-GAAP diluted EPS of $2.06 to $2.21. They reaffirmed this guidance in May 2026. They expect higher revenue compared to 2025, driven by higher device sales and the ramp of the 3870 pump system.